127 related articles for article (PubMed ID: 11563068)
1. Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes.
Düzgünes N; Simões S; Slepushkin V; Pretzer E; Rossi JJ; De Clercq E; Antao VP; Collins ML; de Lima MC
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):515-23. PubMed ID: 11563068
[TBL] [Abstract][Full Text] [Related]
2. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells.
Düzgüneş N; Pretzer E; Simões S; Slepushkin V; Konopka K; Flasher D; de Lima MC
Mol Membr Biol; 1999; 16(1):111-8. PubMed ID: 10332745
[TBL] [Abstract][Full Text] [Related]
3. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems.
Balzarini J; Aquaro S; Perno CF; Witvrouw M; Holý A; De Clercq E
Biochem Biophys Res Commun; 1996 Feb; 219(2):337-41. PubMed ID: 8604988
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of lamivudine and tenofovir.
Franchetti P; Cappellacci L; Petrelli R; Vita P; Grifantini M; Rossi L; Pierigé F; Serafini S; Magnani M; Balestra E; Perno CF
Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):953-7. PubMed ID: 18058516
[TBL] [Abstract][Full Text] [Related]
5. Delivery of antiviral agents in liposomes.
Düzgüneş N; Simões S; Slepushkin V; Pretzer E; Flasher D; Salem II; Steffan G; Konopka K; Pedroso de Lima MC
Methods Enzymol; 2005; 391():351-73. PubMed ID: 15721391
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system.
Lavigne C; Thierry AR
Biochem Biophys Res Commun; 1997 Aug; 237(3):566-71. PubMed ID: 9299405
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir.
Rossi L; Franchetti P; Pierigé F; Cappellacci L; Serafini S; Balestra E; Perno CF; Grifantini M; Caliò R; Magnani M
J Antimicrob Chemother; 2007 Apr; 59(4):666-75. PubMed ID: 17327293
[TBL] [Abstract][Full Text] [Related]
8. Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines.
Balzarini J; Schols D; Van Laethem K; De Clercq E; Hocková D; Masojidkova M; Holý A
J Antimicrob Chemother; 2007 Jan; 59(1):80-6. PubMed ID: 17124193
[TBL] [Abstract][Full Text] [Related]
9. [Resistance in a new light. About mutations and their interactions].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():64-5. PubMed ID: 15011595
[No Abstract] [Full Text] [Related]
10. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Suruga Y; Makino M; Okada Y; Tanaka H; De Clercq E; Baba M
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):316-22. PubMed ID: 9704936
[TBL] [Abstract][Full Text] [Related]
11. Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production.
Zídek Z; Franková D; Holý A
Antimicrob Agents Chemother; 2001 Dec; 45(12):3381-6. PubMed ID: 11709312
[TBL] [Abstract][Full Text] [Related]
12. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Breton G; Alexandre M; Duval X; Prie D; Peytavin G; Leport C; Vildei JL
Scand J Infect Dis; 2004; 36(6-7):527-8. PubMed ID: 15307594
[TBL] [Abstract][Full Text] [Related]
13. Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus.
Perno CF; Santoro N; Balestra E; Aquaro S; Cenci A; Lazzarino G; Di Pierro D; Tavazzi B; Balzarini J; Garaci E; Grimaldi S; Caliò R
Antiviral Res; 1997 Feb; 33(3):153-64. PubMed ID: 9037372
[TBL] [Abstract][Full Text] [Related]
14. Early nonresponse for tenofovir regimen.
AIDS Patient Care STDS; 2003 Nov; 17(11):603. PubMed ID: 14748354
[No Abstract] [Full Text] [Related]
15. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Mulato AS; Cherrington JM
Antiviral Res; 1997 Nov; 36(2):91-7. PubMed ID: 9443665
[TBL] [Abstract][Full Text] [Related]
16. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?
Lavigne C; Yelle J; Sauve G; Thierry AR
AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618
[TBL] [Abstract][Full Text] [Related]
17. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.
Schuetz JD; Connelly MC; Sun D; Paibir SG; Flynn PM; Srinivas RV; Kumar A; Fridland A
Nat Med; 1999 Sep; 5(9):1048-51. PubMed ID: 10470083
[TBL] [Abstract][Full Text] [Related]
18. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.
Cherrington JM; Mulato AS; Fuller MD; Chen MS
Antimicrob Agents Chemother; 1996 Sep; 40(9):2212-6. PubMed ID: 8878611
[TBL] [Abstract][Full Text] [Related]
19. Labeling changes for tenofovir.
AIDS Patient Care STDS; 2004 Jan; 18(1):55. PubMed ID: 15006195
[No Abstract] [Full Text] [Related]
20. Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine.
Smith MS; Brian EL; De Clercq E; Pagano JS
Antimicrob Agents Chemother; 1989 Sep; 33(9):1482-6. PubMed ID: 2479334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
